VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp., resulting in the formation of VERAXA Biotech AG. The company will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. This milestone marks a significant step for the biotech firm as it advances its pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, designed to selectively target cancer cells while sparing healthy tissue.
The business combination is expected to provide VERAXA with the capital and public market presence needed to push its programs toward clinical development. According to the company, proceeds from recently completed financings—including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million—will support the advancement of its BiTAC-TCE and BiTAC-ADC programs. VERAXA recently presented preclinical data at the AACR Annual Meeting 2026 that demonstrated favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate.
The completion of this transaction is important for the biotech industry as it highlights the growing interest in precision oncology approaches. VERAXA's BiTAC platform aims to overcome limitations of traditional T-cell engagers and ADCs by improving tumor targeting while reducing off-tissue toxicity. If successful, these therapies could offer new treatment options for patients with solid tumors, a significant unmet medical need.
For investors, the listing on Nasdaq provides liquidity and transparency, allowing them to track the company's progress. The warrants (VRXAW) offer additional potential upside. However, as with any early-stage biotech, risks remain. The company's forward-looking statements acknowledge uncertainties related to clinical development, regulatory approvals, and competition. Detailed risk factors are outlined in the company's SEC filings.
VERAXA Biotech AG was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution for life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. For regular updates, visit www.veraxa.com.
Voyager Acquisition Corp., the SPAC that merged with VERAXA, is a special purpose acquisition company focused on revolutionizing the healthcare sector through strategic combinations. More information about Voyager can be found at https://www.voyageracq.com. The full press release is available at https://ibn.fm/ka00j.
The completion of this business combination underscores the continued viability of SPACs as a pathway for biotech companies to access public markets. For the oncology field, VERAXA's progress with its BiTAC platform could lead to novel therapies that improve patient outcomes. The industry will be watching closely as the company moves toward clinical trials.
